Sign in
or
Register
0
Add listing
View all results
No results
News
Events
The industry
arrow_drop_down
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Networking platforms
Newsletter
Association
arrow_drop_down
Mission and services
Members
Academy
Partners
Team
Media
Add listing
BAL101553
Product
prev
next
Leave a review
Claim listing
Bookmark
Share
Report
prev
next
Indicaton
Solid tumors (i.e. glioblastoma and ovarian cancer)
Therapeutic indications
Oncology
Type of product
Small molecule
Company
Basilea Pharmaceutica Ltd.
Table
Phase
Phase II started
Partnering status
Not partnered
You may also be interested in
TOP-N53, TOP-V122, TOP-M119 and TOP-N44
TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.
Phase I started
Proclarix
Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.
Marketed
Venofer
Anaemic Dialysis
Marketed
Cart
×
View all results
No results
Facebook
Twitter
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
VKontakte
Mail
Copy link
This site uses cookies:
Find out more.
Accept